Worldwide survey of the results of treating gestational trophoblastic disease
Kohorn, E.I.
Journal of Reproductive Medicine 59(3-4): 145-153
2014
ISSN/ISBN: 0024-7758 PMID: 24724223 Document Number: 671718
To determine factors influencing outcome for patients with gestational trophoblastic disease (GTD) from throughout the world. Physicians known to treat GTD were sent a questionnaire. There were 32 responses from 17 countries, totaling 26,153 patients. Of 14,093 patients with complete mole 20.6% developed trophoblastic neoplasia, and 5.7% died. There were 10,230 patients with partial mole, of whom 6.5% received therapy for neoplasia. There were 548 patients with post-term pregnancy choriocarcinoma, of whom 13.4% died. Of 137 patients with placental site trophoblastic tumor 16.1% died. The remaining 1,165 patients did not fit into a designated diagnostic category. The mortality rate for 2,818 patients with GTD primarily treated at a trophoblast center was 2.1%, as compared with 8% among 1,854 patients referred after failure of primary treatment (p < 0.01). Patients treated by physicians experienced in the management of trophoblastic disease have better results and survival.